Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Nicolaides

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Aging|October 11, 2017
CA125 effects on humoral immunosuppressionJ Bradford Kline, Nicholas C Nicolaides
Plos One|May 17, 2023
NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effectsNicholas C Nicolaides, J Bradford Kline, Luigi Grasso
Antibody Therapeutics|June 30, 2025
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity <i>in vivo</i>Luigi Grasso, Bradford J Kline, Nicholas C Nicolaides
Expert Opinion on Drug Discovery|July 26, 2012
Advances in targeted therapeutic agentsNicholas C Nicolaides, Philip M Sass, Luigi Grasso
Oncology Letters|November 25, 2021
Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppressionLuigi Grasso, James Bradford Kline, Nicholas C Nicolaides
BMC Cancer|June 19, 2026
NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancersNicholas C Nicolaides, James Bradford Kline, Luigi Grasso
European Journal of Immunology|March 20, 2025
ICAM-1 Is Overexpressed by Cancers and Negatively Impacts Antibody-Based Therapies Including Antibody-Drug ConjugatesJ Bradford Kline, Luigi Grasso, Nicholas C Nicolaides
Frontiers in Oncology|July 2, 2014
Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapyNicholas C Nicolaides, Daniel J O'Shannessy, Earl Albone, et al.
European Journal of Immunology|May 5, 2023
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumorsLuigi Grasso, Qun Jiang, Raffit Hassan, et al.
European Journal of Immunology|August 26, 2018
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody bindingJ Bradford Kline, Shawn Fernando, Erin N Ross, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Aging|October 11, 2017
CA125 effects on humoral immunosuppressionJ Bradford Kline, Nicholas C Nicolaides
Plos One|May 17, 2023
NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effectsNicholas C Nicolaides, J Bradford Kline, Luigi Grasso
Antibody Therapeutics|June 30, 2025
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity <i>in vivo</i>Luigi Grasso, Bradford J Kline, Nicholas C Nicolaides
Expert Opinion on Drug Discovery|July 26, 2012
Advances in targeted therapeutic agentsNicholas C Nicolaides, Philip M Sass, Luigi Grasso
Oncology Letters|November 25, 2021
Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppressionLuigi Grasso, James Bradford Kline, Nicholas C Nicolaides
BMC Cancer|June 19, 2026
NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancersNicholas C Nicolaides, James Bradford Kline, Luigi Grasso
European Journal of Immunology|March 20, 2025
ICAM-1 Is Overexpressed by Cancers and Negatively Impacts Antibody-Based Therapies Including Antibody-Drug ConjugatesJ Bradford Kline, Luigi Grasso, Nicholas C Nicolaides
Frontiers in Oncology|July 2, 2014
Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapyNicholas C Nicolaides, Daniel J O'Shannessy, Earl Albone, et al.
European Journal of Immunology|May 5, 2023
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumorsLuigi Grasso, Qun Jiang, Raffit Hassan, et al.
European Journal of Immunology|August 26, 2018
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody bindingJ Bradford Kline, Shawn Fernando, Erin N Ross, et al.
Pageof 3